PURPOSE: The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood. METHODS: We performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, and reactogenicity ≥ 7 days following two doses of mRNA-1273, BNT162b2, or one dose of Ad26.COV2.S. We analyzed responses by multivariate regression and included data from 1,638 healthy controls, previously reported, for comparison. RESULTS: Between April and July 2021, we enrolled 1,001 patients; 762 were eligible for analysis (656 had neutralization measured). mRNA-1273 was the most immunogenic (log10 geometric mean concentration [GMC] 2.9, log10 geometric mean neutralization titer [GMT] 2.3), followed by BNT162b2 (GMC 2.4; GMT 1.9) and Ad26.COV2.S (GMC 1.5; GMT 1.4; P < .001). The proportion of low neutralization (< 20% of convalescent titers) among Ad26.COV2.S recipients was 69.9%. Prior COVID-19 infection (in 7.1% of the cohort) was associated with higher responses (P < .001). Antibody titers and neutralization were quantitatively lower in patients with cancer than in comparable healthy controls, regardless of vaccine type (P < .001). Receipt of chemotherapy in the prior year or current steroids were associated with lower antibody levels and immune checkpoint blockade with higher neutralization. Systemic reactogenicity varied by vaccine and correlated with immune responses (P = .002 for concentration, P = .016 for neutralization). In 32 patients who received an additional vaccine dose, side effects were similar to prior doses, and 30 of 32 demonstrated increased antibody titers (GMC 1.05 before additional dose, 3.17 after dose). CONCLUSION: Immune responses to SARS-CoV-2 vaccines are modestly impaired in patients with cancer. These data suggest utility of antibody testing to identify patients for whom additional vaccine doses may be effective and appropriate, although larger prospective studies are needed.
PURPOSE: The immunogenicity and reactogenicity of SARS-CoV-2 vaccines in patients with cancer are poorly understood. METHODS: We performed a prospective cohort study of adults with solid-organ or hematologic cancers to evaluate anti-SARS-CoV-2 immunoglobulin A/M/G spike antibodies, neutralization, and reactogenicity ≥ 7 days following two doses of mRNA-1273, BNT162b2, or one dose of Ad26.COV2.S. We analyzed responses by multivariate regression and included data from 1,638 healthy controls, previously reported, for comparison. RESULTS: Between April and July 2021, we enrolled 1,001 patients; 762 were eligible for analysis (656 had neutralization measured). mRNA-1273 was the most immunogenic (log10 geometric mean concentration [GMC] 2.9, log10 geometric mean neutralization titer [GMT] 2.3), followed by BNT162b2 (GMC 2.4; GMT 1.9) and Ad26.COV2.S (GMC 1.5; GMT 1.4; P < .001). The proportion of low neutralization (< 20% of convalescent titers) among Ad26.COV2.S recipients was 69.9%. Prior COVID-19 infection (in 7.1% of the cohort) was associated with higher responses (P < .001). Antibody titers and neutralization were quantitatively lower in patients with cancer than in comparable healthy controls, regardless of vaccine type (P < .001). Receipt of chemotherapy in the prior year or current steroids were associated with lower antibody levels and immune checkpoint blockade with higher neutralization. Systemic reactogenicity varied by vaccine and correlated with immune responses (P = .002 for concentration, P = .016 for neutralization). In 32 patients who received an additional vaccine dose, side effects were similar to prior doses, and 30 of 32 demonstrated increased antibody titers (GMC 1.05 before additional dose, 3.17 after dose). CONCLUSION: Immune responses to SARS-CoV-2 vaccines are modestly impaired in patients with cancer. These data suggest utility of antibody testing to identify patients for whom additional vaccine doses may be effective and appropriate, although larger prospective studies are needed.
Authors: Kizzmekia S Corbett; Martha C Nason; Britta Flach; Matthew Gagne; Sarah O'Connell; Timothy S Johnston; Shruti N Shah; Venkata Viswanadh Edara; Katharine Floyd; Lilin Lai; Charlene McDanal; Joseph R Francica; Barbara Flynn; Kai Wu; Angela Choi; Matthew Koch; Olubukola M Abiona; Anne P Werner; Juan I Moliva; Shayne F Andrew; Mitzi M Donaldson; Jonathan Fintzi; Dillon R Flebbe; Evan Lamb; Amy T Noe; Saule T Nurmukhambetova; Samantha J Provost; Anthony Cook; Alan Dodson; Andrew Faudree; Jack Greenhouse; Swagata Kar; Laurent Pessaint; Maciel Porto; Katelyn Steingrebe; Daniel Valentin; Serge Zouantcha; Kevin W Bock; Mahnaz Minai; Bianca M Nagata; Renee van de Wetering; Seyhan Boyoglu-Barnum; Kwanyee Leung; Wei Shi; Eun Sung Yang; Yi Zhang; John-Paul M Todd; Lingshu Wang; Gabriela S Alvarado; Hanne Andersen; Kathryn E Foulds; Darin K Edwards; John R Mascola; Ian N Moore; Mark G Lewis; Andrea Carfi; David Montefiori; Mehul S Suthar; Adrian McDermott; Mario Roederer; Nancy J Sullivan; Daniel C Douek; Barney S Graham; Robert A Seder Journal: Science Date: 2021-09-17 Impact factor: 47.728
Authors: Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber Journal: N Engl J Med Date: 2020-12-10 Impact factor: 91.245
Authors: Wilfredo F Garcia-Beltran; Evan C Lam; Michael G Astudillo; Diane Yang; Tyler E Miller; Jared Feldman; Blake M Hauser; Timothy M Caradonna; Kiera L Clayton; Adam D Nitido; Mandakolathur R Murali; Galit Alter; Richelle C Charles; Anand Dighe; John A Branda; Jochen K Lennerz; Daniel Lingwood; Aaron G Schmidt; A John Iafrate; Alejandro B Balazs Journal: Cell Date: 2020-12-15 Impact factor: 41.582
Authors: Lindsey R Baden; Hana M El Sahly; Brandon Essink; Karen Kotloff; Sharon Frey; Rick Novak; David Diemert; Stephen A Spector; Nadine Rouphael; C Buddy Creech; John McGettigan; Shishir Khetan; Nathan Segall; Joel Solis; Adam Brosz; Carlos Fierro; Howard Schwartz; Kathleen Neuzil; Larry Corey; Peter Gilbert; Holly Janes; Dean Follmann; Mary Marovich; John Mascola; Laura Polakowski; Julie Ledgerwood; Barney S Graham; Hamilton Bennett; Rolando Pajon; Conor Knightly; Brett Leav; Weiping Deng; Honghong Zhou; Shu Han; Melanie Ivarsson; Jacqueline Miller; Tal Zaks Journal: N Engl J Med Date: 2020-12-30 Impact factor: 91.245
Authors: Katherine McMahan; Jingyou Yu; Noe B Mercado; Carolin Loos; Lisa H Tostanoski; Abishek Chandrashekar; Jinyan Liu; Lauren Peter; Caroline Atyeo; Alex Zhu; Esther A Bondzie; Gabriel Dagotto; Makda S Gebre; Catherine Jacob-Dolan; Zhenfeng Li; Felix Nampanya; Shivani Patel; Laurent Pessaint; Alex Van Ry; Kelvin Blade; Jake Yalley-Ogunro; Mehtap Cabus; Renita Brown; Anthony Cook; Elyse Teow; Hanne Andersen; Mark G Lewis; Douglas A Lauffenburger; Galit Alter; Dan H Barouch Journal: Nature Date: 2020-12-04 Impact factor: 49.962
Authors: J Barrière; E Chamorey; Z Adjtoutah; O Castelnau; A Mahamat; S Marco; E Petit; A Leysalle; V Raimondi; M Carles Journal: Ann Oncol Date: 2021-04-28 Impact factor: 32.976
Authors: Evangelos Terpos; Ioannis P Trougakos; Maria Gavriatopoulou; Ioannis Papassotiriou; Aimilia D Sklirou; Ioannis Ntanasis-Stathopoulos; Eleni-Dimitra Papanagnou; Despina Fotiou; Efstathios Kastritis; Meletios A Dimopoulos Journal: Blood Date: 2021-07-01 Impact factor: 22.113
Authors: William A Werbel; Brian J Boyarsky; Michael T Ou; Allan B Massie; Aaron A R Tobian; Jacqueline M Garonzik-Wang; Dorry L Segev Journal: Ann Intern Med Date: 2021-06-15 Impact factor: 25.391
Authors: Florian Krammer; Komal Srivastava; Hala Alshammary; Angela A Amoako; Mahmoud H Awawda; Katherine F Beach; Maria C Bermúdez-González; Dominika A Bielak; Juan M Carreño; Rachel L Chernet; Lily Q Eaker; Emily D Ferreri; Daniel L Floda; Charles R Gleason; Joshua Z Hamburger; Kaijun Jiang; Giulio Kleiner; Denise Jurczyszak; Julia C Matthews; Wanni A Mendez; Ismail Nabeel; Lubbertus C F Mulder; Ariel J Raskin; Kayla T Russo; Ashley-Beathrese T Salimbangon; Miti Saksena; Amber S Shin; Gagandeep Singh; Levy A Sominsky; Daniel Stadlbauer; Ania Wajnberg; Viviana Simon Journal: N Engl J Med Date: 2021-03-10 Impact factor: 91.245
Authors: Grace M Choong; Savannah Liddell; Roberto A Leon Ferre; Ciara C O'Sullivan; Kathryn J Ruddy; Tufia C Haddad; Timothy J Hobday; Prema P Peethambaram; Minetta C Liu; Matthew P Goetz; Karthik V Giridhar Journal: Breast Cancer Res Treat Date: 2022-08-31 Impact factor: 4.624
Authors: Sherin Juliet Rouhani; Jovian Yu; Daniel Olson; Yuanyuan Zha; Apameh Pezeshk; Alexandra Cabanov; Athalia R Pyzer; Jonathan Trujillo; Benjamin A Derman; Peter O'Donnell; Andrzej Jakubowiak; Hedy L Kindler; Christine Bestvina; Thomas F Gajewski Journal: J Immunother Cancer Date: 2022-06 Impact factor: 12.469
Authors: Vivek Naranbhai; Kerri J St Denis; Evan C Lam; Onosereme Ofoman; Wilfredo F Garcia-Beltran; Cristhian B Mairena; Atul K Bhan; Justin F Gainor; Alejandro B Balazs; A John Iafrate Journal: Cancer Cell Date: 2022-01-05 Impact factor: 31.743
Authors: Cynthia L Bowes; Vivek Naranbhai; Kerri J St Denis; Evan C Lam; Brittany Bertaux; Florence K Keane; Melin J Khandekar; Alejandro B Balazs; John A Iafrate; Justin F Gainor; Henning Willers Journal: Radiother Oncol Date: 2021-11-25 Impact factor: 6.280